Chronic Obstructive Pulmonary Disease (COPD) – Market Insight, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Chronic Obstructive Pulmonary Disease (COPD) – Market Insight, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Chronic Obstructive Pulmonary Disease (COPD) Disease overview, pathogenesis, identified and emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Clinical Trial Landscaping, Probable launch date estimation Regulatory framework, Epidemiology; Incidence, Prevalence, and current therapy market share, Order of entry, patient share, Market uptake, Peak patient share, Disease burden, Annual cost of therapy, the market forecast for the USA, Germany, France, Italy, Spain, UK, Japan and China 2020 to 2030


1. Chronic Obstructive Pulmonary Disease (COPD) – Key Findings Summary
1.1. Clinical findings
1.1.1. Disease overview
1.1.2. Therapeutic practices
1.1.3. Future outlook
1.2. Commercial findings
1.2.1. Chronic Obstructive Pulmonary Disease (COPD) market scenario 2020
1.2.2. Chronic Obstructive Pulmonary Disease (COPD) market scenario 2025
1.2.3. Chronic Obstructive Pulmonary Disease (COPD) market scenario 2030
2. Chronic Obstructive Pulmonary Disease (COPD) Overview
2.1. Disease Introduction
2.2. Pathophysiology
2.3. Signs and Symptoms
2.4. Risk Factors
2.5. Etiology
2.6. Classification
2.7. Pathogenesis
2.8. Diagnosis
2.9. Complications
2.10. Treatment Algorithm
2.10.1. Treatment in US (guidelines)
2.10.2. Treatment in EU-5 (guidelines)
2.10.3. Treatment in Japan (guidelines)
2.10.4. Treatment in China (guidelines)
2.11. Treatment Goals for Chronic Obstructive Pulmonary Disease (COPD)
2.12. Referral Patterns
2.12.1. Referral Scenario in US
2.12.2. Referral Scenario in EU-5
2.12.3. Referral Scenario in Japan
2.12.4. Referral Scenario in China
2.13.Chronic Obstructive Pulmonary Disease (COPD) Prognosis
2.14.Healthcare burden
2.14.1. Healthcare burden in US
2.14.2. Healthcare burden in EU-5
2.14.3. Healthcare burden in Japan
2.14.4. Healthcare burden in China
2.15. Unmet Needs in Chronic Obstructive Pulmonary Disease (COPD) management
2.16. Market Opportunity for Chronic Obstructive Pulmonary Disease (COPD)
2.17. KOL Comments on current and upcoming/expected treatment practices in Chronic Obstructive Pulmonary Disease (COPD)
3. Epidemiology
3.1. Epidemiology Overview
3.2. Epidemiology by Geography
3.2.1. Chronic Obstructive Pulmonary Disease (COPD) Epidemiology in US (2019-2030)
3.2.1.1. Incidence of Chronic Obstructive Pulmonary Disease (COPD)
3.2.1.2. Diagnosed cases
3.2.1.3. Treatable Patient Pool
3.2.1.4. Epidemiology Trends
3.2.2. Chronic Obstructive Pulmonary Disease (COPD) Epidemiology in EU-5 (2019-2030)
3.2.2.1. Incidence of Chronic Obstructive Pulmonary Disease (COPD)
3.2.2.2. Diagnosed cases
3.2.2.3. Treatable Patient Pool
3.2.2.4. Epidemiology Trends
3.2.3. Chronic Obstructive Pulmonary Disease (COPD) Epidemiology in Japan (2019-2030)
3.2.3.1. Incidence of Chronic Obstructive Pulmonary Disease (COPD)
3.2.3.2. Diagnosed cases
3.2.3.3. Treatable Patient Pool
3.2.3.4. Epidemiology Trends
3.2.4. Chronic Obstructive Pulmonary Disease (COPD) Epidemiology in China (2019-2030)
3.2.4.1. Incidence of Chronic Obstructive Pulmonary Disease (COPD)
3.2.4.2. Diagnosed cases
3.2.4.3. Treatable Patient Pool
3.2.4.4. Epidemiology Trends
3.3. Epidemiology Trends (World-wide)
4. Market Outlook
4.1. US Chronic Obstructive Pulmonary Disease (COPD) Market Forecast 2019-2030
4.1.1. Market Progression (Futuristic)
4.1.2. Market Trends and Expectations
4.1.2.1. Worst case scenario
4.1.2.2. Base Case Scenario
4.1.2.3. Best Case Scenario
4.1.3. Drivers and Barriers
4.2. UK Chronic Obstructive Pulmonary Disease (COPD) Market Forecast 2019-2030
4.2.1. Market Progression (Futuristic)
4.2.2. Market Trends and Expectations
4.2.2.1. Worst case scenario
4.2.2.2. Base Case Scenario
4.2.2.3. Best Case Scenario
4.2.3. Drivers and Barriers
4.3. France Chronic Obstructive Pulmonary Disease (COPD) Market Forecast 2019-2030
4.3.1. Market Progression (Futuristic)
4.3.2. Market Trends and Expectations
4.3.2.1. Worst case scenario
4.3.2.2. Base Case Scenario
4.3.2.3. Best Case Scenario
4.3.3. Drivers and Barriers
4.4. Germany Chronic Obstructive Pulmonary Disease (COPD) Market Forecast 2019-2030
4.4.1. Market Progression (Futuristic)
4.4.2. Market Trends and Expectations
4.4.2.1. Worst case scenario
4.4.2.2. Base Case Scenario
4.4.2.3. Best Case Scenario
4.4.3. Drivers and Barriers
4.5. Italy Chronic Obstructive Pulmonary Disease (COPD) Market Forecast 2019-2030
4.5.1. Market Progression (Futuristic)
4.5.2. Market Trends and Expectations
4.5.2.1. Worst case scenario
4.5.2.2. Base Case Scenario
4.5.2.3. Best Case Scenario
4.5.3. Drivers and Barriers
4.6. Spain Chronic Obstructive Pulmonary Disease (COPD) Market Forecast 2019-2030
4.6.1. Market Progression (Futuristic)
4.6.2. Market Trends and Expectations
4.6.2.1. Worst case scenario
4.6.2.2. Base Case Scenario
4.6.2.3. Best Case Scenario
4.6.3. Drivers and Barriers
4.7. Japan Chronic Obstructive Pulmonary Disease (COPD) Market Forecast 2019-2030
4.7.1. Market Progression (Futuristic)
4.7.2. Market Trends and Expectations
4.7.2.1. Worst case scenario
4.7.2.2. Base Case Scenario
4.7.2.3. Best Case Scenario
4.7.3. Drivers and Barriers
4.8. China Chronic Obstructive Pulmonary Disease (COPD) Market Forecast 2019-2030
4.8.1. Market Progression (Futuristic)
4.8.2. Market Trends and Expectations
4.8.2.1. Worst case scenario
4.8.2.2. Base Case Scenario
4.8.2.3. Best Case Scenario
4.8.3. Drivers and Barriers
4.9. Key Expected Milestones (world-wide) Impacting the Market
5. Competitive Landscape
5.1. Pipeline Therapies Overview
5.1.1. Phase III Therapies
5.1.1.1. Current Status
5.1.1.2. Trial details, results
5.1.1.3. Approval Timeline
5.1.1.4. Likelihood of approval
5.1.1.5. Expected Product Positioning
5.1.1.2. All other Phase III Therapies …..
5.1.1.3. Attribute Analysis of Phase III molecules
5.1.2. Phase II and Phase I/II Therapies
5.1.2.1. Current Status
5.1.2.2. Trial details, results
5.1.2.3. Approval Timelines
5.1.3. List of active Pre-clinical Therapies
5.1.3.1. Status in Chronic Obstructive Pulmonary Disease (COPD)
5.1.3.2. Company positioning
5.1.3.2. All other pre-clinical therapies
5.1.4. List of Inactive/discontinued assets
5.1.4.1. Business impact of discontinuations on current pipeline
5.1.5. Potential winners from Chronic Obstructive Pulmonary Disease (COPD) Pipeline
5.1.5.1. Potential Blockbusters across the pipeline
6. Regulatory/Approval Scenario
6.1. Regulatory/Approval Framework in US
6.1.1. Policy Framework
6.1.2. Payer Expectations
6.2. Regulatory/Approval Framework in UK
6.2.1. Policy Framework
6.2.2. Payer Expectations
6.3. Regulatory/Approval Framework in France
6.3.1. Policy Framework
6.3.2. Payer Expectations
6.4. Regulatory/Approval Framework in Germany
6.4.1. Policy Framework
6.4.2. Payer Expectations
6.5. Regulatory/Approval Framework in Italy
6.5.1. Policy Framework
6.5.2. Payer Expectations
6.6. Regulatory/Approval Framework in Spain
6.6.1. Policy Framework
6.6.2. Payer Expectations
6.7. Regulatory/Approval Framework in Japan
6.7.1. Policy Framework
6.7.2. Payer Expectations
6.8. Regulatory/Approval Framework in China
6.8.1. Policy Framework
6.8.2. Payer Expectations
7. Clinical Trial Assessment – Current and Future Paradigm
7.1. Distribution of Primary Endpoints across trials
7.2. Distribution of Secondary Endpoints across trials
7.3. Evolution and acceptance of surrogate endpoints
7.4. Key Investigator initiated trials
7.5. Attrition analysis
7.5.1. Suspended/Discontinued Assets
7.5.2. Failed Trials, Reasons and Business Impact
7.5.3. Terminated Trials, Reasons and Business Impact
7.5.4. Withdrawn Trials, Reasons and Business Impact
7.6. Trial enrollment scenario and challenges
7.7. Clinical Trial Guidance (across geographies)
8. Thelansis Commentary
8.1. Key Unmet needs in Chronic Obstructive Pulmonary Disease (COPD)
8.2. Possible Best-case Clinical Trial Strategies
8.3. Possible Best Case Targeted Product Profile (TPP)
8.4. Possible Best-case Market positioning strategies
8.5. Possible Best-case Market Access Strategies
8.6. Possible Best-case LCM Strategies
8.7. Overall View on Chronic Obstructive Pulmonary Disease (COPD) Market in Dollar Value
9. Report Methodology
9.1. Secondary research
9.2. Primary research
9.3. Data collation
9.4. Insight Generation
10. About Thelansis
10.1. Our Capabilities
10.2. Our Services
10.3. Our Contacts
10.4. Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings